NICE favours Cell Therapeutics' Pixuvri/Bayer's Eylea PharmaTimes In final draft guidance, the Appraisal Committee concluded that Pixuvri is indeed cost-effective, but only for patients who have previously been treated with MabThera (rituximab) and those receiving third or fourth line treatment. In these scenarios ... |
